300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Financial Services
Construction
Mobile
Retail
Payments
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Software
Blockchain
Theatre
Beauty
Medical
Fashion
Infrastructure
Social
Celebrity
Web3
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Recruiting
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
Social Media
FinTech
Franchise
Internet
Mobile Advertising
Android
Impact
Enterprise
Community
Media (Entertainment)
Proptech
Hardware
Transportation
Biotech
Sustainability
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
New Zealand
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Paraguay
Moldova
Seychelles
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Asia
Dominican Republic
Bermuda
Albania
Spain
Bangladesh
Angola
Barbados
Europe
Belgium
Cyprus
Austria
Ethiopia
Jordan
Qatar
Azerbaijan
Ecuador
Bahamas
Bulgaria
Bolivia
Belize
Algeria
Belarus
Finland
Bahrain
Italy
Hungary
Grenada
Israel
Jersey
Honduras
Lithuania
Estonia
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Merck, VC Fund

Merck

VC Fund

Kenilworth, United States

Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases. The company is driven by a mission to discover, develop, and provide innovative products and services that save and improve lives.

Total investments:
31
Last investment:
Lead investor:
29%
Fund size:
$131
Last fund:

Last updated:

Industries Merck invests in

Health CareBiotechnologyMedicalTherapeuticsGenetics

Stages Merck invests in

Series AFunding RoundSeedSeries BSeries C

Countries Merck invests in

United StatesCanadaChinaIndiaMexico

Round sizes

Seed $2.6M–$3.3MSeries A $7.8M–$120M

Contacts

NameEmailPhoneSocials
See all 16 contacts →

Sign up to unlock verified contacts

Unlock Contacts

Round size

Seed
$2.6M–$3.3M
Series A
$7.8M–$120M

Investment Focus

Industry

  • Health Care 17 (55%)
  • Biotechnology 17 (55%)
  • Medical 9 (29%)
  • Therapeutics 7 (23%)
  • Genetics 5 (16%)
See all 34 industries →

Stage

  • Series A 6 (19%)
  • Funding Round 4 (13%)
  • Seed 3 (10%)
  • Series B 3 (10%)
  • Series C 2 (6%)
See all 12 stages →

Country

  • United States 19 (61%)
  • Canada 2 (6%)
  • China 1 (3%)
  • India 1 (3%)
  • Mexico 1 (3%)
See all 9 countries →

Team

NameTitleInvestmentsLinksEmail
Charles Pigneri
Charles Pigneri Associate Director Regional Marketing-RML
Associate Director Regional Marketing-RML Total investments: 0
Find email
Fiona Marshall
Fiona Marshall Senior Vice President Head of Discovery Sciences and Translational Medicine
Senior Vice President Head of Discovery Sciences and Translational Medicine Total investments: 0
Find email
Pamela Craig
Pamela Craig Member of The Board of Directors
Member of The Board of Directors Total investments: 0
Find email
Peter Dudek
Peter Dudek President & Managing Partner, MRL Ventures Fund
President & Managing Partner, MRL Ventures Fund Total investments: 5
Find email
Seth Staples
Seth Staples Senior Scientist, Vaccine Process Development & Commercialization
Senior Scientist, Vaccine Process Development & Commercialization Total investments: 0
Find email
See all 16 team members →

Investments

CompanyDescriptionRoundLinks
Saturnus Bio
Saturnus Bio is a precision cardiology company utilizing targeted gene modulation to address rare mono genetic cardiomyopathies with significant unmet need. Corporate Round / Jun 23, 2026
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics. The company was founded in 2021 and is headquartered in Belmont, California. $120M / Series A / Nov 17, 2025
HD HD
HD is a healthcare and surgery marketplace, powering over 1,500+ healthcare providers including some of the biggest hospitals. HD connects patients to hospitals, clinics, operating rooms, and surgeons while offering healthcare financing solutions to increase access to affordable care and surgeries. To date, over 250,000 patients have benefited frommore accessible and affordable healthcare and surgeries through the company's platform. $7.8M / Series A / Feb 12, 2025
Personalis combines both the technology of sequencing and interpretation, with an extensive history of peer-reviewed publication and commercial success. It is providing an extensive molecular view of a patient’s tumor and characterizes its interplay with the immune system. It aids in the development of safer, effective precision cancer therapies,immunotherapies, and personalized medicines. $50M / Post-IPO Equity / Dec 19, 2024
Friends of Puerto Rico is a nonpartisan, non-profit social impact group that advocates for economic growth. and education through result-oriented entrepreneurial ventures centered on sustainability and self-sufficiency. $190K / Grant / May 27, 2024
Oatmeal Health is an AI lung cancer diagnostic company that plugs directly into partners’ CADe/PACS systems, turning routine CT scans into reimbursable malignancy‑risk reads under CPT 0721T/0722T without changing radiologist workflow. By layering a nodule‑level, longitudinal risk score on top of existing detection tools, we reduce falsepositives and unnecessary biopsies while creating a new $650‑per‑scan revenue line for imaging centers and health systems. We use joint-venture agreements with platforms like Coreline, so a single integration unlocks entire hospital networks rather than a site-by-site sales model. $175K / Non-equity Assistance / Mar 15, 2024
Prognos Health is a leading health tech company that is pushing the boundaries of healthcare analytics. The company’s platform, prognosFACTOR, has the power to query billions of lab and health records on more than 325 million de-identified patients to answer clinically-focused healthcare questions in minutes, not months. The platform enables thequerying and purchasing of patient-centric, HIPAA-Compliant healthcare data from the Prognos Marketplace to address diverse applications, including cohort design, patient journey studies, health outcomes and more. Customers include 25 of the top 30 pharmaceutical manufacturers and three of the top five payers. $23.3M / May 04, 2023
Mamotest is a data-driven patient end-to-end solution defeating breast cancer. It goes from awareness and high-quality imaging diagnosis to patient journey follow-up. We collect medical and clinical data and care for psychological and socio-economic data. That broader scope with 100% patient traceability allows us to put vital information in thehands of global business and policy decision-makers, giving them the power to save hundreds of thousands of women's lives. $3.3M / Seed / Mar 27, 2023
At Qure.ai their mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients. $40M / Series C / Mar 29, 2022
Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates invarious stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington. $1B / Post-IPO Equity / Sep 14, 2020
See all 31 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Financial Services
Construction
Mobile
Retail
Payments
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Software
Blockchain
Theatre
Beauty
Medical
Fashion
Infrastructure
Social
Celebrity
Web3
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Recruiting
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
Social Media
FinTech
Franchise
Internet
Mobile Advertising
Android
Impact
Enterprise
Community
Media (Entertainment)
Proptech
Hardware
Transportation
Biotech
Sustainability
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
New Zealand
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Paraguay
Moldova
Seychelles
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Asia
Dominican Republic
Bermuda
Albania
Spain
Bangladesh
Angola
Barbados
Europe
Belgium
Cyprus
Austria
Ethiopia
Jordan
Qatar
Azerbaijan
Ecuador
Bahamas
Bulgaria
Bolivia
Belize
Algeria
Belarus
Finland
Bahrain
Italy
Hungary
Grenada
Israel
Jersey
Honduras
Lithuania
Estonia
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Merck invest in?

Merck invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Funding Round stage. Most of the 31 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Merck invest in?

Merck typically joins rounds of $2.6M–$3.3M at Seed and $7.8M–$120M at Series A. These are whole funding-round sizes, not Merck's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Merck took part in.

How do I contact Merck?

Public channels for Merck include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Merck?

The team at Merck includes Charles Pigneri (Associate Director Regional Marketing-RML), Fiona Marshall (Senior Vice President Head of Discovery Sciences and Translational Medicine) and Pamela Craig (Member of The Board of Directors), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Merck Merck Find emails